GHRH Analogs Class Overview Monograph

What Are GHRH Analogs and How Do They Work?

GHRH analogs are synthetic peptides modeled on the 44-amino-acid endogenous hypothalamic hormone that normally triggers pulsatile GH release from somatotroph cells. By binding the pituitary GHRH receptor, they drive GH secretion while leaving intact the somatostatin-mediated negative feedback loop. That preserved feedback mechanism is the central pharmacologic distinction between this class and direct recombinant GH replacement.

The Endogenous GHRH Axis

Endogenous GHRH is a 44-amino-acid peptide secreted from hypothalamic arcuate neurons in a pulsatile pattern. It reaches anterior pituitary somatotrophs via the portal circulation, activates the Gs-coupled GHRH receptor, and raises intracellular cyclic AMP. The resulting calcium influx triggers GH exocytosis. Somatostatin, released from periventricular nuclei, opposes this signal, creating the characteristic pulsatile GH secretory pattern that drives downstream IGF-1 production in the liver [1].

Age-related GH decline, sometimes called somatopause, involves reduced GHRH pulse amplitude rather than pituitary failure, which is part of the rationale for using GHRH analogs rather than replacing GH directly [2].

How Analogs Differ from the Endogenous Molecule

Native GHRH has a plasma half-life of roughly 7 minutes, limiting its clinical use. Medicinal chemistry has addressed this in two main ways. First, truncating the molecule to residues 1-29 (sermorelin) retains full agonist activity while simplifying synthesis. Second, modifying the N-terminus with a trans-3-hexenoic acid group (tesamorelin) extends stability and extends half-life to approximately 26-38 minutes [3]. CJC-1295 incorporates a drug affinity complex (DAC) that covalently binds albumin after injection, extending its half-life to several days, though it lacks FDA approval.

Agents in the Class: Approved and Compounded

The GHRH analog class contains a handful of clinically active compounds. Only tesamorelin carries an FDA-approved indication. Sermorelin was FDA-approved for pediatric GH deficiency but had its NDA voluntarily withdrawn in 2008 by the manufacturer; it is now available only through compounding pharmacies. CJC-1295 has never received FDA approval.

Tesamorelin (Egrifta SV)

Tesamorelin (trade name Egrifta SV, 2 mg formulation) received FDA approval in November 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [4]. The approval was based on two phase 3 randomized controlled trials (LIPO-010 and LIPO-011, combined N = 816). In the pooled analysis, tesamorelin 2 mg subcutaneously once daily produced a statistically significant 15.2% mean reduction in visceral adipose tissue (VAT) measured by CT scan at 26 weeks compared with a 0.6% increase in the placebo group (P<0.001) [5]. Trunk fat reductions were accompanied by modest improvements in triglycerides and patient-reported body image scores. Effects on VAT did not persist after discontinuation, which supports continuous rather than episodic dosing for this indication.

The FDA label carries warnings for neoplasm risk in patients with active malignancy, fluid retention, glucose intolerance, and hypersensitivity reactions. Tesamorelin is contraindicated in pregnancy [4].

Sermorelin Acetate

Sermorelin, the 1-29 amino-terminal fragment of GHRH, was the first synthetic GHRH analog to enter clinical use. Pediatric GH deficiency trials in the 1990s showed that nightly subcutaneous sermorelin 30 mcg/kg increased mean 24-hour GH secretion and improved height velocity [6]. The voluntary 2008 NDA withdrawal by Serono reflected commercial rather than safety reasons. Today, sermorelin is compounded at doses typically ranging from 200 to 500 mcg subcutaneously at bedtime, timed to coincide with natural nocturnal GH pulses. Compounding pharmacies operate under 503A or 503B frameworks; prescribers should verify their pharmacy's FDA registration status.

CJC-1295

CJC-1295 with DAC extends GHRH signaling by maintaining elevated plasma GH across days rather than discrete pulses. A phase 1/2 dose-escalation study in 21 healthy adults showed that a single subcutaneous injection of CJC-1295 with DAC (30-60 mcg/kg) produced mean GH increases of 2- to 10-fold lasting for 6 days, with IGF-1 elevations of 1.5- to 3-fold persisting for up to 14 days [7]. The blunting of pulsatility raises theoretical concerns about desensitization of the GHRH receptor over time, though long-term human data are limited. CJC-1295 without DAC (also called modified GRF 1-29) has a shorter half-life and more closely mimics physiologic pulsatility.

Combination With GHRPs

Clinicians frequently combine GHRH analogs with growth hormone-releasing peptides (GHRPs) such as ipamorelin or GHRP-2. These two classes act synergistically: GHRH analogs increase the number of somatotrophs responsive to a secretory stimulus, while GHRPs amplify the amplitude of each pulse via the ghrelin receptor. One crossover pharmacodynamic study (N = 32) demonstrated that co-administration of GHRH plus GHRP-6 produced mean GH peaks roughly three to five times higher than either agent alone [8]. Prescribers should account for this potentiation when titrating doses and monitoring IGF-1.

Pharmacokinetics Across the Class

Absorption and Distribution

All approved and compounded GHRH analogs are administered subcutaneously. Bioavailability for tesamorelin is reported at approximately 4% after subcutaneous injection, reflecting significant proteolytic degradation at the injection site and in plasma [3]. Despite low absolute bioavailability, sufficient peptide reaches the pituitary portal circulation to produce measurable GH responses within 15-30 minutes of injection.

Metabolism and Elimination

GHRH analogs are metabolized by ubiquitous serine proteases, primarily dipeptidyl peptidase IV (DPP-IV), which cleaves the N-terminal Tyr-Ala bond and rapidly inactivates native GHRH and sermorelin. Tesamorelin's trans-3-hexenoic acid modification at position 1 confers DPP-IV resistance, contributing to its longer half-life compared with sermorelin. Renal impairment has limited impact on clearance given the peptide metabolism pathway; no dose adjustment for tesamorelin is specified in the FDA label for renal or hepatic impairment [4].

Monitoring IGF-1 as a Surrogate

Because GH itself is difficult to measure reliably outside controlled research settings due to its pulsatility, IGF-1 serves as the primary pharmacodynamic biomarker in clinical practice. The Endocrine Society recommends targeting an IGF-1 in the mid-normal range for the patient's age and sex during GH-stimulating therapy [9]. IGF-1 should be checked at baseline, at 4-6 weeks after dose initiation or titration, and every 6 months during stable therapy. An IGF-1 consistently above the upper limit of normal warrants dose reduction or temporary discontinuation.

Clinical Evidence Base

Tesamorelin RCT Data

The phase 3 EGRIFTA program remains the most rigorously controlled data set for any GHRH analog. In a 26-week double-blind RCT followed by a 26-week extension phase (total N = 412 in the extension), tesamorelin maintained significant VAT reductions at 52 weeks in patients who continued active treatment. Patients switched from tesamorelin to placebo at week 26 regained VAT to near-baseline levels by week 52, confirming that ongoing therapy is required for sustained benefit [5]. Triglyceride reductions of approximately 50 mg/dL were observed in patients with baseline hypertriglyceridemia.

Sermorelin in Aging Adults

A 6-month double-blind RCT by Vittone et al. (N = 89) evaluated sermorelin 2 mg subcutaneously every night in adults aged 60-80 years. Mean IGF-1 rose 30% from baseline in the sermorelin group versus 1% in placebo (P<0.001). Lean body mass increased by approximately 1.5 kg, and fat mass declined by approximately 0.9 kg, though no statistically significant differences in physical performance scores were observed at 6 months [6]. This study is commonly cited in anti-aging contexts, though sermorelin does not carry FDA approval for age-related GH decline.

IGF-1 Normalization as a Therapeutic Target

The following decision framework is used by the HealthRX medical team to guide GHRH analog titration in adults receiving compounded sermorelin off-label. It is not a published guideline.

1. Check baseline IGF-1, fasting glucose, HbA1c, and a lipid panel.
2. Start sermorelin at 200 mcg subcutaneously at bedtime.
3. Recheck IGF-1 at 6 weeks. If IGF-1 remains below the age-adjusted 50th percentile and the patient tolerates the drug, increase to 300 mcg.
4. Target IGF-1 in the age- and sex-adjusted 50th-75th percentile range, never exceeding the upper limit of normal.
5. Recheck fasting glucose at 12 weeks; if FPG rises above 100 mg/dL from a normal baseline, reassess risk-benefit.
6. At 6 months, reassess clinical goals. If no objective improvement in at least one measurable outcome (lean mass, VAT, IGF-1), consider discontinuation.

Dosing and Administration

Approved Dosing: Tesamorelin

The FDA-approved dose of tesamorelin (Egrifta SV) is 2 mg subcutaneously once daily, injected into the abdomen [4]. The 2 mg/vial formulation (Egrifta SV) replaced the original 1 mg formulation (Egrifta) in 2019 to allow once-daily single-vial dosing. Injection site rotation within the abdomen is required; tesamorelin must not be injected into scar tissue, bruised areas, or the navel. Reconstitution uses sterile water for injection provided in the kit.

Compounded Sermorelin Dosing

For compounded sermorelin, doses in telehealth and anti-aging practices typically range from 100 to 500 mcg at bedtime. Bedtime dosing takes advantage of the physiologic nocturnal GH pulse and the concurrent decline in somatostatin tone during slow-wave sleep. Some protocols specify 5-days-on, 2-days-off cycling to reduce receptor tachyphylaxis, though controlled data supporting this specific cycling pattern in humans are absent. Dose adjustments are guided by IGF-1 response as described in the titration framework above.

CJC-1295 Dosing Considerations

Compounded CJC-1295 with DAC is typically dosed at 1-2 mg subcutaneously once weekly. Without the DAC modification (modified GRF 1-29), dosing resembles sermorelin: 100-200 mcg subcutaneously at bedtime, often co-administered with ipamorelin 100-200 mcg in the same syringe. Mixing GHRH analogs and GHRPs in the same syringe is pharmacokinetically feasible given compatible pH ranges, but prescribers should confirm compatibility with the compounding pharmacy's formulation data.

Safety Profile and Adverse Effects

Glucose Dysregulation

GH is physiologically counter-regulatory to insulin. Elevated GH reduces peripheral glucose uptake and increases hepatic glucose output. Tesamorelin's FDA label reports that 4.7% of treated patients developed diabetes mellitus versus 2.2% of placebo patients across the phase 3 trials [4]. HbA1c rose by a mean of 0.12% in tesamorelin-treated HIV patients at 26 weeks. For patients with pre-existing type 2 diabetes or impaired fasting glucose, the risk-benefit assessment requires careful individualization and more frequent glucose monitoring.

Fluid Retention and Related Effects

GH stimulates renal sodium retention through IGF-1-mediated effects on the distal nephron. Peripheral edema, arthralgia, myalgia, and carpal tunnel syndrome are class effects shared with exogenous GH therapy. In the tesamorelin RCTs, edema was reported in 6.3% of treated patients versus 3.2% of controls [5]. Symptoms typically resolve with dose reduction. Patients with pre-existing heart failure or severe edema require close monitoring.

Neoplasm Risk

GH and IGF-1 are mitogenic. Active malignancy is a contraindication to tesamorelin per the FDA label [4]. The Endocrine Society guidelines on GH therapy note that there is no established evidence that GH-stimulating therapy initiates de novo malignancies, but it may theoretically promote proliferation of occult tumors [9]. Annual skin surveillance and maintenance of cancer screening appropriate to the patient's age and risk profile are recommended during long-term therapy.

Injection-Site Reactions

Pain, erythema, and nodule formation at the injection site were reported in approximately 8-10% of tesamorelin trial participants [5]. Proper injection technique, rotation of sites, and allowing the reconstituted solution to reach room temperature before injection reduce these reactions.

Antibody Formation

Up to 49% of patients treated with tesamorelin for 52 weeks develop anti-tesamorelin antibodies, the majority cross-reactive with native GHRH. The FDA label notes that antibody formation was not associated with loss of efficacy or adverse events in the phase 3 trials [4]. Long-term implications of sustained antibody titers in patients receiving compounded analogs are unknown.

Contraindications and Drug Interactions

Absolute contraindications for the class include: active malignancy, disruption of the hypothalamic-pituitary axis by surgery, radiation, or trauma (which would eliminate the target tissue for GHRH analogs), hypersensitivity to the agent or its components, and pregnancy.

Drug interactions are modest. Glucocorticoids suppress GH release both at the hypothalamic and pituitary levels; patients on pharmacologic corticosteroid doses may show blunted IGF-1 responses to GHRH analogs [9]. Somatostatin analogs (octreotide, lanreotide) directly oppose GHRH-mediated GH release and should not be co-prescribed for GH-stimulating purposes. Oral estrogen reduces hepatic GH sensitivity and may require higher GHRH analog doses to achieve target IGF-1 levels compared with transdermal estrogen delivery [9].

Regulatory and Compounding Considerations

FDA Approval Status

Only tesamorelin (Egrifta SV, Theratechnologies) holds current FDA approval, restricted to HIV-associated lipodystrophy in adults [4]. Sermorelin's NDA was voluntarily withdrawn in 2008. No other GHRH analog currently holds an approved NDA or BLA in the United States.

Compounding Pharmacy Framework

Sermorelin, modified GRF 1-29, and CJC-1295 are widely compounded under section 503A (patient-specific prescriptions) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. The FDA maintains a list of bulk drug substances that may be used in compounding; prescribers should verify that their pharmacy operates under a current registration and that the specific peptide is permissible under the applicable nominations list. FDA enforcement activity in the peptide compounding space has increased since 2023, including warning letters to pharmacies compounding unapproved GH secretagogues [10].

Off-Label Prescribing

Prescribing a compounded GHRH analog for indications other than HIV-associated lipodystrophy (for example, age-related GH decline, athletic performance, or body composition in non-HIV adults) is off-label by definition. Informed consent documentation should specify: the off-label nature of the therapy, the evidence base and its limitations, the FDA approval status, the compounding source, and anticipated monitoring requirements.

Patient Selection and Monitoring Protocol

Candidate Characteristics

Adults who may benefit from GHRH analog therapy generally share these features: biochemical GH deficiency confirmed by stimulation testing per Endocrine Society criteria [9], or established HIV-associated lipodystrophy with excess VAT for tesamorelin. Stimulation testing using glucagon, insulin tolerance, or macimorelin (Macrilen, FDA-approved GH stimulation test since 2017 [11]) should precede prescribing of any GH-stimulating agent when GH deficiency is the indication.

Monitoring Schedule

A practical monitoring schedule for prescribers:

• Baseline: IGF-1, fasting glucose, HbA1c, lipid panel, CBC, comprehensive metabolic panel, and cancer-screening documentation appropriate to age.
• Week 6: IGF-1, fasting glucose. Adjust dose based on IGF-1.
• Month 3: IGF-1, fasting glucose, HbA1c. Assess for fluid retention symptoms.
• Month 6: Full baseline panel repeated. Assess body composition if available. Decide on continuation.
• Every 6 months thereafter: IGF-1, fasting glucose, HbA1c, lipid panel.

The Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency in adults specifies: "We recommend IGF-1 be measured every 1-2 months during dose titration and then every 6 months once the maintenance dose has been established" [9].

Special Populations

Adults With HIV-Associated Lipodystrophy

Tesamorelin is the standard pharmacologic option for excess VAT in this population. The EGRIFTA trials enrolled adults with HIV on stable antiretroviral therapy, with baseline VAT above 130 cm² by CT. Prescribers should note that protease inhibitors, particularly older agents, contribute to lipodystrophy through direct effects on adipocyte differentiation independent of GH status [5]. Tesamorelin addresses the GH-axis component of VAT excess; switching antiretroviral regimens to integrase inhibitor-based regimens may further improve metabolic outcomes.

Older Adults

GH secretion declines approximately 14% per decade after age 30 [2]. The therapeutic window for GHRH analogs in healthy older adults is narrow: adequate GH stimulation to improve body composition without producing supraphysiologic IGF-1, glucose intolerance, or fluid overload. Starting doses should be at the lower end of the range (sermorelin 100-200 mcg at bedtime), with titration guided strictly by IGF-1 response.

Patients With Diabetes

HbA1c must be below 8% before initiating a GHRH analog in a patient with existing type 2 diabetes, given the glucose-counterregulatory effects of GH. More frequent glucose monitoring (every 4-6 weeks during the first 6 months) is warranted, and the prescribing clinician should coordinate with the patient's endocrinologist or primary care provider managing the diabetes.